MANGALAM vs SPARC: Stock Comparison

Mangalam Drugs And Organics Limited vs Sun Pharma Advanced Research Company Limited

Live data: 22 July 2026, 2:55 PM IST • Source: NSE and company filings

Sun Pharma Advanced Research Company Limited is the larger company by market capitalisation. Sun Pharma Advanced Research Company Limited shows a higher ROE, faster revenue growth and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Mangalam Drugs And Organics Limited and Sun Pharma Advanced Research Company Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, MANGALAM is more favourable on 0 of 11 scored metrics and SPARC on 9These counts are context-free and are not an overall rating.

Key Differences

Market Cap
SPARC is the larger company
₹6,943 Cr vs ₹43 Cr
EPS
SPARC has higher earnings per share
₹49.21 vs ₹-28.05
Revenue Growth (TTM YoY)
SPARC has faster revenue growth
6,716.8% vs -7.5%
Qtr Sales Growth
SPARC has stronger quarterly sales growth
6,716% vs -7.54%
Qtr Profit Growth
SPARC has stronger quarterly profit growth
3,047% vs -22,467%
ROE
SPARC has a higher ROE
279% vs -35.2%
ROCE
SPARC has a higher ROCE
164% vs -14.3%
Net Margin
SPARC has a higher net margin
82.65% vs -19.13%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricMANGALAMSPARC
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricMANGALAMSPARC
Live Price₹27.08₹213.74
Day Change-0.66%-4.8%
Volume25,35617.67 L
52-Week High₹95₹289
52-Week Low₹22.8₹108
Distance from 52W High-71.49%-26.04%

Valuation

MetricMANGALAMSPARC
Market Cap₹43 Cr₹6,943 Cr
P/E Ratio4.71x
P/B Ratio5.47x
EPS₹-28.05₹49.21
Book Value₹65.12₹41.25
Dividend Yield0%0%

Growth

MetricMANGALAMSPARC
Revenue Growth (TTM YoY)-7.5%6,716.8%
EPS Growth (TTM YoY)0%0%
Qtr Sales Growth-7.54%6,716%
Qtr Profit Growth-22,467%3,047%

Profitability & Leverage

MetricMANGALAMSPARC
ROE-35.2%279%
ROCE-14.3%164%
Net Margin-19.13%82.65%
Operating Margin-6.42%85.1%
Debt to Equity1.02x0.42x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricMANGALAMSPARC
Promoter Holding35.65%65.67%
FII Holding0.11% 0.21 pp2.04%
DII Holding0%0.88% 0.1 pp
Public Holding64.24% 0.22 pp31.41% 0.1 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Mangalam Drugs And Organics Limited and Sun Pharma Advanced Research Company Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.